 | Douglas A DrossmanShow email addressRome Foundation, Raleigh, NC, USA | UNC Center for Functional GI and Motility Disorders, Durham, NC, USA | Center for Functional GI and Motility Disorders, University of North ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Douglas A Drossman:Expert Impact
Concepts for whichDouglas A Drossmanhas direct influence:Irritable bowel syndrome,Bowel syndrome,Irritable bowel,Abdominal pain,Psychosocial factors,Medical schools,Narcotic bowel syndrome,Gastrointestinal illness.
Douglas A Drossman:KOL impact
Concepts related to the work of other authors for whichfor which Douglas A Drossman has influence:Irritable bowel syndrome,Abdominal pain,Functional dyspepsia,Inflammatory bowel disease,Ibs patients,Chronic constipation,Quality life.
KOL Resume for Douglas A Drossman
| Year | |
|---|---|
| 2021 | Rome Foundation, Raleigh, NC, USA Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Education and Practice of Biopsychosocial Care, Drossman Gastroenterology, Chapel Hill, North Carolina. |
| 2020 | Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, NC, USA |
| 2019 | Center for Education and Practice of Biopsychosocial Care, Center for Functional GI and Motility Disorders, University of North Carolina, Drossman Gastroenterology, Chapel Hill NC, and the Rome Foundation, Raleigh NC, USA |
| 2018 | Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, and Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology, Chapel Hill, North Carolina |
| 2017 | UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, 55 Vilcom Center Drive, Suite 110, 27514, Chapel Hill, NC, USA From the Department of Internal Medicine, Division of Gastroenterology (Aroniadis), Montefiore Medical Center-Albert Einstein College of Medicine, Bronx, New York; Center for Functional Gastrointestinal and Motility Disorders (Drossman, Simrén), University of North Carolina at Chapel Hill, North Carolina; Drossman Gastroenterology (Drossman, Simrén), Chapel Hill, North Carolina; and Department of Internal Medicine and Clinical Nutrition (Simrén), Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden. Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, NC. Department of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC |
| 2016 | Center for Education and Practice of Biopsychosocial Care, Drossman Gastroenterology, Chapel Hill, NC, USA Rome Foundation, Chapel Hill, North Carolina |
| 2015 | University of North Carolina at Chapel Hill Drossman Center for the Education and Practice of Biopsychosocial Care Professor Emeritus of Medicine and Psychiatry UNC Center for Functional GI and Motility Disorders Chapel Hill NC USA |
| 2014 | Professor Emeritus of Medicine and Psychiatry, Center for Functional GI and Motility Disorders, University of North Carolina, President, Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology PLLC, Chapel Hill, NC. UNC Center for Functional GI and Motility Disorders Drossman Gastroenterology PLLC Chapel Hill NC USA University of North Carolina and Drossman Gastroenterology PLLC, Chapel Hill |
| 2013 | The Drossman Center for the Education & Practice of Biopsychosocial Care, LLC, Chapel Hill, North Carolina Drossman Center for the Education and Practice of Biopsychosocial Care LLC, and UNC Center for Functional GI and Motility Disorders, Chapel Hill, NC, USA |
| 2012 | Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Medicine, Clinical Sciences Building, Cork University Hospital, Cork, Ireland |
| 2011 | Codirector, Center for Functional GI and Motility Disorders Professor of Medicine and Psychiatry School of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina. UNC Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, USA Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina |
| 2010 | UNC Center for Functional GI and Motility Disorders, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA |
| Concept | World rank |
|---|---|
| ibsar baseline severity | #1 |
| abuse measure paper | #1 |
| sexual physical abuse | #1 |
| linear causative fashion | #1 |
| structural disease studies | #1 |
| specific cultural contributions | #1 |
| form pprs | #1 |
| anticipated difficulty patients | #1 |
| disease symptoms depression | #1 |
| antibody reactivity autoantigens | #1 |
| studies symptom criteria | #1 |
| openlabel lubiprostone | #1 |
| clinical trials fgid | #1 |
| patients opioidsthe mechanisms | #1 |
| gerson respect | #1 |
| work gerson | #1 |
| entities epidemiological data | #1 |
| faps health impact | #1 |
| safety lubiprostone doses | #1 |
| factors illness condition | #1 |
| flare increased disability | #1 |
| narcotic bowel | #1 |
| role psychotropic agents | #1 |
| oic clinical | #1 |
| health pretending | #1 |
| ibsc ibsd | #1 |
| health behavior dysfunction | #1 |
| ∼5 patients | #1 |
| documents journal issue | #1 |
| physicians perceptions patients | #1 |
| endoscopic sphincter ablation | #1 |
| p0001 data | #1 |
| conclusions respects | #1 |
| 522 ibsc patients | #1 |
| foster international networks | #1 |
| prevalence bowel dysfunction | #1 |
| caps result | #1 |
| sexual 53 | #1 |
| gastrointestinal disorders model | #1 |
| gutbrain interaction | #1 |
| major trauma abuse | #1 |
| ercp interventions manometry | #1 |
| documents description | #1 |
| central neuromodulators treatments | #1 |
| ibs psychosocial | #1 |
| 32 16 microg | #1 |
| functional illnesses | #1 |
| opportunities enhanced physician | #1 |
| production documents | #1 |
| sexual abuse comparison | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Douglas A Drossman
IMPORTANCE: Abdominal pain after cholecystectomy is common and may be attributed to sphincter of Oddi dysfunction. Management often involves endoscopic retrograde cholangiopancreatography (ERCP) with manometry and sphincterotomy.
OBJECTIVE: To determine whether endoscopic sphincterotomy reduces pain and whether sphincter manometric pressure is predictive of pain relief.
DESIGN, SETTING, AND PATIENTS: Multicenter, sham-controlled, randomized trial involving 214 patients with pain after ...
| Known for Endoscopic Sphincterotomy | Suspected Sphincter | Ercp Patients | Abdominal Pain | Oddi Dysfunction |
Irritable Bowel Syndrome Subtypes Defined by Rome II and Rome III Criteria are Similar
[ PUBLICATION ]
BACKGROUND: The implications of the Rome III recommendations to change the irritable bowel syndrome (IBS) subtype criteria for stool pattern are unknown.
AIM: (1) Determine the level of agreement between Rome II and Rome III subtypes and (2) compare the behaviors of Rome II and Rome III subtypes over time.
METHODS: Female patients (n=148) with Rome II defined IBS were prospectively tracked over 5 consecutive 3-month periods. At baseline, bowel habit reports on questionnaires were used to ...
| Known for Rome Iii | Irritable Bowel | Illness Surveys Questionnaires | Subtypes Time | Ibs Subtype |
Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women
[ PUBLICATION ]
OBJECTIVES: Using interview data from a large, community-based sample of American women, we assessed the lifetime prevalence of irritable bowel syndrome (IBS) using questions consistent with the Rome II criteria, determined the sensitivity of Rome I and II in women diagnosed with IBS by their community physician, and identified whether there are differences in the patients identified by Rome I versus II.
METHODS: A geographically diverse national probability sample of women diagnosed ...
| Known for Ibs Rome | Irritable Bowel | Specificity Surveys | Community Sample | Screening Interviews |
Contributions of Pain Sensitivity and Colonic Motility to IBS Symptom Severity and Predominant Bowel Habits
[ PUBLICATION ]
OBJECTIVES: Irritable bowel syndrome (IBS) patients show pain hypersensitivity and hypercontractility in response to colonic or rectal distention. Aims were to determine whether predominant bowel habits and IBS symptom severity are related to pain sensitivity, colon motility, or smooth muscle tone.
METHODS: One hundred twenty-nine patients classified as IBS with diarrhea (IBS-D, N = 44), IBS with constipation (IBS-C, N = 29), mixed IBS (IBS-M, N = 45), and unspecified IBS (IBS-U, N = 11) ...
| Known for Pain Sensitivity | Ibs Symptom Severity | Colonic Motility | Bowel Habit | Illness Surveys |
Randomized Controlled Trial Shows Biofeedback to be Superior to Pelvic Floor Exercises for Fecal Incontinence
[ PUBLICATION ]
PURPOSE: This study aimed to compare manometric biofeedback with pelvic floor exercises for the treatment of fecal incontinence in a randomized controlled trial controlling for nonspecific treatment effects.
METHODS: After excluding patients who were adequately treated with medication, education, and behavioral strategies (21%), 108 patients (83 females; average age, 59.6 years) underwent either pelvic floor exercises alone (n = 63) or manometric biofeedback plus pelvic floor exercises ...
| Known for Fecal Incontinence | Pelvic Floor | Randomized Controlled Trial | Biofeedback Patients | Life Illness |
BACKGROUND & AIMS: Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD). We also evaluated the ...
| Known for Behavioral Therapy | Functional Bowel Disorders | Versus Placebo | Diarrhea Female Humans | Pla Fbd |
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
[ PUBLICATION ]
OBJECTIVE: To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components.
DESIGN: A six week single blind three arm randomised controlled ...
| Known for Irritable Bowel Syndrome | Controlled Trial | Quality Life | Adequate Relief | Waiting List |
Patient education improves clinical outcomes in patients with chronic illness, but little is known about the education needs of patients with IBS.
OBJECTIVES: The objective of this study was to identify: (1) patients perceptions about IBS; (2) the content areas where patients feel insufficiently informed, i.e., "knowledge gaps" about diagnosis, treatment options, etiology, triggers, prognosis, and role of stress; and (3) whether there are differences related to items 1 and 2 among ...
| Known for Patient Education | National Survey | Irritable Bowel | Chronic Illness | Syndrome Ibs |
A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator
[ PUBLICATION ]
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is subtyped as IBS with diarrhea (IBS-D) or IBS with constipation (IBS-C) based on Rome II guidelines. The remaining group is considered as having mixed IBS (IBS-M). There is no standard definition of an alternator (IBS-A), in which bowel habit changes over time. Our aim was to use Rome II criteria to prospectively assess change in bowel habit for more than 1 year to understand IBS-A.
METHODS: Female patients (n=317) with IBS entering a ...
| Known for Bowel Habit | Ibsd Ibsc | Prospective Assessment | Rome Criteria | 1 Year |
Validation of Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: A Critical Review
[ PUBLICATION ]
This article reviews the evidence for validity of symptom-based criteria (Manning, Rome I, Rome II, and Rome III) for irritable bowel syndrome (IBS). Two kinds of validations are reported: (i) studies testing whether symptom criteria discriminate patients with structural disease at colonoscopy from patients without structural disease; and (ii) studies testing whether symptom criteria discriminate patients presumed to have IBS by positive diagnosis from healthy subjects or patients with ...
| Known for Irritable Bowel Syndrome | Rome Criteria | Sensitivity Specificity | Symptoms Ibs | Symptom Based |
AimsThe aim of this study is to assess the efficacy and safety of lubiprostone in adults with chronic constipation.MethodsThis multicenter, parallel-group trial enrolled 237 patients with chronic constipation and randomized them to 4 weeks of double-blind treatment with oral lubiprostone 24 mcg or placebo twice daily. The primary efficacy endpoint was the number of spontaneous bowel movements (SBMs) after 1 week of treatment. Secondary evaluations included SBMs at weeks 2, 3, and 4; ...
| Known for Chronic Constipation | Lubiprostone Patients | Sbms Week | Efficacy Safety | Abdominal Bloating |
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist
[ PUBLICATION ]
BACKGROUND: No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly through 5HT3-receptors.
AIM: To evaluate effects of the 5HT3-receptor antagonist, alosetron, in irritable bowel syndrome.
METHODS: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2, 4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable ...
| Known for Bowel Function | Adequate Relief | 5‐ht3 Receptor Antagonist | Stool Consistency | Alosetron Treatment |
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation
[ PUBLICATION ]
BACKGROUND: Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation.
AIM: To assess the efficacy and safety of three lubiprostone doses for irritable bowel syndrome with constipation.
METHODS: 195 irritable bowel syndrome with constipation patients received daily doses of 16 [8 microg twice daily (b.d.)], 32 (16 microg b.d.) or 48 microg (24 microg b.d.) lubiprostone or placebo b.d. for 3 months. ...
| Known for Irritable Bowel Syndrome | Lubiprostone Treatment | Clinical Trial | Constipation Patients | Efficacy Safety |
Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J)
[ PUBLICATION ]
AIMS: To compare quality of life (QOL) for patients with irritable bowel syndrome (IBS) between the U.S. and Japan, it is indispensable to develop common instruments. The IBS-QOL, which is widely used in Western countries, was translated into Japanese as there has been a lack of Japanese disease-specific QOL measures for IBS.
METHODS: The original 34 items of the IBS-QOL were translated from English into Japanese through two independent forward translations, resolution, back translation, ...
| Known for Ibs Qol | Japanese Version | Irritable Bowel | Rome Criteria | Internal Consistency |
